Benzinga | Jul 31, 2020 01:24PM EDT

Piper Sandler Initiates Coverage On NGM Biopharmaceuticals with Overweight Rating, Announces Price Target of $30

Piper Sandler analyst Yasmeen Rahimi initiates coverage on NGM Biopharmaceuticals (NASDAQ:NGM) with a Overweight rating and announces Price Target of $30.